8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
NCT00230581
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
88
Enrollment
INDUSTRY
Sponsor class
Conditions
Irritable Bowel Syndrome
Interventions
DRUG:
DDP225
Sponsor
Dynogen Pharmaceuticals